Apilimod

• Description:

  Apilimod (STA 5326) is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC50s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively[1]. Apilimod is a potent and highly selective PIKfyve inhibitor.

• Product Name Alternative:

  STA 5326; LAM-002A (free base) ; AIT-101

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H335

• Target:

  Interleukin Related; PIKfyve

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation; PI3K/Akt/mTOR

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Apilimod.html

• Purity:

  99.80

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CC1=CC=CC(/C=N/NC2=CC(N3CCOCC3)=NC(OCCC4=CC=CC=N4)=N2)=C1

• Molecular Formula:

  C23H26N6O2

• Molecular Weight:

  418.49

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]Wada Y, et al. Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood. 2007 Feb 1;109 (3) :1156-64.|[2]Keino H, et al. Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis. Arthritis Res Ther. 2008;10 (5) :R122.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• Isoform:

  IL-12; IL-23; IL-4; IL-5; IL-8

• Citation 01:

  Biomaterials. 2022 Jun;285:121509.|bioRxiv. 2020 Jun 15:2020.04.21.053058.|bioRxiv. 2023 Apr 28:2023.04.26.538482.|bioRxiv. 2023 Aug 12.|bioRxiv. 2023 Aug 28.|bioRxiv. 2023 Oct 20:2023.10.19.563158.|bioRxiv. 2024 May 10.|biorxiv. 2024 May 27.|bioRxiv. 2025 June 02.|bioRxiv. 2025 March 19.|bioRxiv. 2025 Nov 3:2025.11.02.686178.|Biotechnol J. 2023 Feb;18 (2) :e2200147.|Br J Cancer. 2020 Aug;123 (4) :542-555.|Cancer Lett. 2023 Nov 28:577:216435.|Cell Mol Life Sci. 2016 Dec;73 (24) :4717-4737. |Commun Biol. 2022 Mar 24;5 (1) :262.|Commun Biol. 2025 Aug 6;8 (1) :1169.|Exp Mol Med. 2024 Aug;56 (8) :1736-1749.|J Biol Chem. 2023 Jan;299 (1) :102775.|J Cell Biol. 2025 Feb 3;224 (2) :e202401136.|J Virol. 2021 Oct 13;95 (21) :e0097521.|Mol Biol Cell. 2022 Mar 1;33 (3) :ar26.|Mol Cell Biol. 2025;45 (3) :99-115.|Nat Commun. 2020 Mar 27;11 (1) :1620.|Nat Commun. 2025 May 28;16 (1) :4945.|PLoS Pathog. 2023 Feb 24;19 (2) :e1011202.|PLoS Pathog. 2025 Jan 2;21 (1) :e1012800.|Proc Natl Acad Sci U S A. 2023 Dec 26;120 (52) :e2307423120.|Proc Natl Acad Sci U S A. 2024 May 21;121 (21) :e2403685121.|Sci Adv. 2022 Jul 22;8 (29) :eabn1440.|Sci Adv. 2023 Oct 13;9 (41) :eadh1134.|SSRN. 2024 Jan 26.|Theranostics. 2020 Mar 4;10 (9) :3925-3938.|Vaccine. 2025 Jul 23:62:127537.|Viruses. 2021 Jun 28;13 (7) :1255.|Viruses. 2023 Jun 12;15 (6) :1353.|bioRxiv. 2023 Aug 12.|bioRxiv. 2024 Jan 23.

• CAS Number:

  [541550-19-0]